Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells

Goya, Kayoko; Sumitani, Satoru; Xu, Xin; Kitamura, Tetsuhiro; Yamamoto, Hiroyasu; Kurebayashi, Shogo; Saito, Hiroshi; Kouhara, Haruhiko; Kasayama, Soji; Kawase, Ichiro

doi:10.1161/01.atv.0000118682.58708.78

Cited by 174Peroxisome Proliferator-Activated ReceptorsNitric Oxide and Endothelin EffectsParaoxonase enzyme and polymorphisms

Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells

Goya, Kayoko, Sumitani, Satoru, Xu, Xin, Kitamura, Tetsuhiro, Yamamoto, Hiroyasu, Kurebayashi, Shogo, Saito, Hiroshi, Kouhara, Haruhiko +2 more·2004·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/01.atv.0000118682.58708.78

Open this paper in CoChat — free account

Abstract

Objective— There has been accumulating evidence demonstrating that activators for peroxisome proliferator-activated receptor α (PPARα) have antiinflammatory, antiatherogenic, and vasodilatory effects. We hypothesized that PPARα activators can modulate endothelial nitric oxide synthase (eNOS) expression and its activity in cultured vascular endothelial cells. Methods and Results— Bovine aortic endothelial cells were treated with the PPARα activator fenofibrate. The amount of eNOS activity and the expression of eNOS protein and its mRNA were determined. Our data show that treatment with fenofibrate for 48 hours resulted in an increase in eNOS activity. Fenofibrate failed to increase eNOS activity within 1 hour. Fenofibrate also increased eNOS protein as well as its mRNA levels. RU486, which has been shown to antagonize PPARα action, inhibited the fenofibrate-induced upregulation of eNOS protein expression. WY14643 and bezafibrate also increased eNOS protein levels, whereas rosiglitazone did not. Transient transfection experiments using human eNOS promoter construct showed that fenofibrate failed to enhance eNOS promoter activity. Actinomycin D studies demonstrated that the half-life of eNOS mRNA increased with fenofibrate treatment. Conclusions— PPARα activators upregulate eNOS expression, mainly through mechanisms of stabilizing eNOS mRNA. This is a new observation to explain one of the mechanisms of PPARα-mediated cardiovascular protection.

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000118682.58708.78

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diep et al. and Goya et al. reported that FF increases endothelial Nitric Oxide (NO) availability.
“Diep et al. [101] and Goya et al. [102] reported that FF increases endothelial Nitric Oxide (NO) availability.”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [102]

A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y. I., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,716 · see citing works
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678 · see citing works
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591 · see citing works
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D. J., Gratton, J., McCabe, T. J. D., Fontana, J. T., Fujio, Y., Walsh, K. X., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,585 · see citing works
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · see citing works
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · see citing works
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.
Caterina, R. D., Libby, P., Peng, H., Thannickal, V. J., Rajavashisth, T. B., Gimbrone, M. A., Shin, W. S., & Liao, J. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118074 · Cited by 1,781 · see citing works
Nitric Oxide Is Responsible for Flow-Dependent Dilatation of Human Peripheral Conduit Arteries In Vivo
Joannidès, R., Haefeli, W. E., Linder, L., Richard, V. J., Bakkali, E. H., Thuillez, C., & Lüscher, T. F. (1995) · Circulation · doi:10.1161/01.cir.91.5.1314 · Cited by 1,622 · see citing works
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi‐Moghadam, A., Brazil, D. P., Ley, K. F., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,437 · see citing works
Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay
Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,221 · see citing works
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
Staels, B., Köenig, W., Habib, A., Merval, R., Lebret, M., Pineda‐Torra, I., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,134 · see citing works
Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.
Förstermann, U., Closs, E. I., Pollock, J. S., Nakane, M., Schwarz, P., Gath, I., & Kleinert, H. (1994) · Hypertension · doi:10.1161/01.hyp.23.6.1121 · Cited by 1,115 · see citing works
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089 · see citing works
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 845 · see citing works
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
Hernández‐Perera, O., Pérez‐Sala, D., Navarro-Antolı́n, J., Sánchez-Pascuala, R., Hernández, G., Dı́az-Jullien, C., & Lamas, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1500 · Cited by 758 · see citing works
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Steiner, G. A. (2001) · Cited by 732 · see citing works
Endothelin stimulates c‐fos and c‐myc expression and proliferation of vascular smooth muscle cells
Komuro, I., Kurihara, H., Sugiyama, T., Takaku, F., & Yazaki, Y. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80489-7 · Cited by 726 · see citing works
PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells
Marx, N., Sukhova, G. K., Collins, T., Libby, P., & Plutzky, J. (1999) · Circulation · doi:10.1161/01.cir.99.24.3125 · Cited by 597 · see citing works
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase
Hafezi‐Moghadam, A., Simoncini, T., Yang, Z., Limbourg, F. P., Plumier, J.-C., Rebsamen, M. C., Hsieh, C.-M., Chui, D.-S., Thomas, K. L., Prorock, A. J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-473 · Cited by 595 · see citing works
IL‐6 and NF‐IL6 in Acute‐Phase Response and Viral Infection
Akira, S., & Kishimoto, T. (1992) · Immunological Reviews · doi:10.1111/j.1600-065x.1992.tb01407.x · Cited by 531 · see citing works
Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo
Xin, X., Yang, S., Kowalski, J., & Gerritsen, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.9116 · Cited by 508 · see citing works
Peroxisome Proliferator-Activated Receptor Activators Inhibit Thrombin-Induced Endothelin-1 Production in Human Vascular Endothelial Cells by Inhibiting the Activator Protein-1 Signaling Pathway
Delerive, P., Martin‐Nizard, F., Chinetti, G., Trottein, F., Fruchart, J., Najïb, J., Duriez, P., & Staels, B. (1999) · Circulation Research · doi:10.1161/01.res.85.5.394 · Cited by 502 · see citing works
ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULES IN HUMAN DISEASE
Bevilacqua, M. P., Nelson, R. M., Mannori, G., & Cecconi, O. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.361 · Cited by 456 · see citing works
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
Vu‐Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J., Staels, B., & Auwerx, J. H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118118 · Cited by 397 · see citing works
Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice.
Moroi, M., Zhang, L., Yasuda, T., Virmani, R., Gold, H., Fishman, M. C., & Huang, P. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1293 · Cited by 337 · see citing works
Peroxisome Proliferator-Activated Receptor γ Ligands Increase Release of Nitric Oxide From Endothelial Cells
Calnek, D. S., Mazzella, L., Roser, S., Roman, J., & Hart, C. M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000044461.01844.c9 · Cited by 286 · see citing works
Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions
Seino, Y., Ikeda, U., Ikeda, M., Yamamoto, K., Misawa, Y., Hasegawa, T., Kano, S., & Shimada, K. (1994) · Cytokine · doi:10.1016/1043-4666(94)90013-2 · Cited by 263 · see citing works
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
Young, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., et al. (1998) · PubMed · Cited by 229 · see citing works
Functional Analysis of the Human Endothelial Nitric Oxide Synthase Promoter
Zhang, R., Wang, M., & Sessa, W. C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.15320 · Cited by 225 · see citing works
Peroxisome Proliferator-Activated Receptor-α Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment
Deplanque, D., Gelé, P., Pétrault, O., Six, I., Furman, C., Bouly, M., Nion, S., Dupuis, B., Leys, D., Fruchart, J., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06264.2003 · Cited by 219 · see citing works
Expression of Peroxisome Proliferator-Activated Receptor α (PPARα) in Primary Cultures of Human Vascular Endothelial Cells
Inoue, I., Shino, K., Noji, S., Awata, T., & Katayama, S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8622 · Cited by 199 · see citing works
PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages
NEVE, B. P., Corseaux, D., Chinetti, G., Zawadzki, C., Fruchart, J., Duriez, P., Staels, B., & Jude, B. (2001) · Circulation · doi:10.1161/01.cir.103.2.207 · Cited by 191 · see citing works
The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.
Walker, A. B., Chattington, P., Buckingham, R. E., & Williams, G. (1999) · Diabetes · doi:10.2337/diabetes.48.7.1448 · Cited by 185 · see citing works
Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
Ruotolo, G., Ericsson, C.-G., Tettamanti, C., Karpe, F., Grip, L., Svane, B., Nilsson, J. Å., Fairé, U. D., & Hamsten, A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00442-2 · Cited by 158 · see citing works
Micronised Fenofibrate
Adkins, J. C., & Faulds, D. M. (1997) · Drugs · doi:10.2165/00003495-199754040-00007 · Cited by 136 · see citing works
A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity
Brown, P. J., Winegar, D. A., Plunket, K. D., Moore, L. B., Lewis, M. C., Wilson, J. G., Sundseth, S. S., Koble, C. S., Wu, Z., Chapman, J. M., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9903601 · Cited by 128 · see citing works
Nitric Oxide and Vascular Disease
Loscalzo, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330410 · Cited by 114 · see citing works
Effect of Bezafibrate Treatment Over Five Years on Coronary Plaques Causing 20% to 50% Diameter Narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])
Ericsson, C.-G., Nilsson, J. Å., Grip, L., Svane, B., & Hamsten, A. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00626-7 · Cited by 90 · see citing works
Interleukin 6 gene transcripts are expressed in atherosclerotic lesions of genetically hyperlipidemic rabbits
Ikeda, U., Ikeda, M., Seino, Y., Takahashi, M., Kano, S., & Shimada, K. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90280-t · Cited by 88 · see citing works
An Estrogen-Inducible Protein Binds Specifically to a Sequence in the 3′ Untranslated Region of Estrogen-Stabilized Vitellogenin mRNA
Dodson, R. E., & Shapiro, D. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.5.3130-3138.1994 · Cited by 84 · see citing works
Short-Term Triglyceride Lowering With Fenofibrate Improves Vasodilator Function in Subjects With Hypertriglyceridemia
Capell, W. H., DeSouza, C. A., Poirier, P., Bell, M. L., Stauffer, B. L., Weil, K. M., Hernandez, T. L., & Eckel, R. H. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000046230.02211.b4 · Cited by 84 · see citing works
PPARα and GR Differentially Down-Regulate the Expression of Nuclear Factor-κB-Responsive Genes in Vascular Endothelial Cells
Xu, X., Otsuki, M., Saito, H., Sumitani, S., Yamamoto, H., Asanuma, N., Kouhara, H., & Kasayama, S. (2001) · Endocrinology · doi:10.1210/endo.142.8.8340 · Cited by 82 · see citing works
Self-citation
Interleukin-6 stimulates c-myc expression and proliferation of cultured vascular smooth muscle cells.
Nabata, T., Morimoto, S., Koh, E., Shiraishi, T., & Ogihara, T. (1990) · PubMed · Cited by 81 · see citing works
Activation of the peroxisome proliferator-activated receptor α protects against myocardial ischaemic injury and improves endothelial vasodilatation
Tabernero, A., Schoonjans, K., Jesel, L., Carpusca, I., Auwerx, J. H., & Andriantsitohaina, R. (2002) · BMC Pharmacology · doi:10.1186/1471-2210-2-10 · Cited by 77 · see citing works
Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
Playford, D. A., Watts, G. F., Best, J. D., & Burke, V. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02847-3 · Cited by 75 · see citing works
Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells
Flowers, M. A., Wang, Y., Stewart, R. J., Patel, B., & Marsden, P. A. (1995) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1995.269.6.h1988 · Cited by 74 · see citing works
RU486 antagonizes the inhibitory effect of peroxisome proliferator-activated receptor α on interleukin-6 production in vascular endothelial cells
Xu, X., Otsuki, M., Sumitani, S., Saito, H., Kouhara, H., & Kasayama, S. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00055-9 · Cited by 12 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 706 · see citing works
An overview on biological mechanisms of PPARs
Kota, B. P., Huang, T. H.-W., & Roufogalis, B. D. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 671 · see citing works
Inflammation in Hypertension
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 551 · see citing works
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646 · see citing works
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501 · see citing works
Nitric oxide and atherosclerosis: An update
Claudio Napoli, A., de Nigris, F., Williams‐Ignarro, S., Pignalosa, O., Sica, V., & Ignarro, L. J. (2006) · Nitric Oxide · doi:10.1016/j.niox.2006.03.011 · Cited by 463 · see citing works
Thirty Years of Saying NO
Vanhoutte, P. M., Zhao, Y., Xu, A., & Leung, S. W. S. (2016) · Circulation Research · doi:10.1161/circresaha.116.306531 · Cited by 391 · see citing works
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado‐López, F., & Moore‐Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 351 · see citing works
Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation
Du, X., Edelstein, D., Obici, S., Higham, N., Zou, M., & Brownlee, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci23354 · Cited by 344 · see citing works
Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice
Kim, M. Y., Lim, J. H., Youn, H. H., Hong, Y. A., Yang, K. S., Park, H., Chung, S., Koh, S. H., Shin, S. J., Choi, B. S., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2747-2 · Cited by 313 · see citing works
Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes
Vanweert, F., Schrauwen, P., & Phielix, E. (2022) · Nutrition and Diabetes · doi:10.1038/s41387-022-00213-3 · Cited by 316 · see citing works
Inflammation in hypertension
Savoia, C., & Schiffrin, E. L. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mnh.0000203189.57513.76 · Cited by 286 · see citing works
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 289 · see citing works
Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases
Napoli, C., & Ignarro, L. J. (2009) · Archives of Pharmacal Research · doi:10.1007/s12272-009-1801-1 · Cited by 281 · see citing works
PPARα in atherosclerosis and inflammation
Zandbergen, F. J., & Plutzky, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.021 · Cited by 215 · see citing works
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 205 · see citing works
Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Seo, Y., Choi, I. S., & Shin, E. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.052 · Cited by 199 · see citing works
Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Jay, M., & Ren, J. T. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802067 · Cited by 196 · see citing works
Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
Jasińska-Stroschein, M., Owczarek, J., & Orszulak–Michalak, D. (2007) · PubMed · Cited by 192 · see citing works
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications
Touyz, R. M., & Schiffrin, E. L. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.014 · Cited by 152 · see citing works
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease
Robinson, E., & Grieve, D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.003 · Cited by 130 · see citing works
The year in atherothrombosis
Moreno, P., & Fuster, V. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.077 · Cited by 128 · see citing works
PPARs and other nuclear receptors in inflammation
RIZZO, G., & Fiorucci, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.012 · Cited by 127 · see citing works
Age-Associated Molecular Changes in the Kidney in Aged Mice
Lim, J. H., Kim, E. N., Kim, M. Y., Chung, S., Shin, S. J., Kim, H. W., Yang, C. W., Kim, Y., Chang, Y. S., Park, C. W., et al. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/171383 · Cited by 127 · see citing works
Fenofibrate Improves Renal Lipotoxicity through Activation of AMPK-PGC-1α in db/db Mice
Hong, Y. A., Lim, J. H., Kim, M. Y., Kim, T. W., Kim, Y., Yang, K. S., Park, H. S., Choi, S. R., Chung, S., Kim, H. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096147 · Cited by 118 · see citing works
PPAR-α activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway
Bulhak, A., Jung, C., Östenson, C., Lundberg, J. O., Sjöquist, P.-O. B., & Pernow, J. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00394.2008 · Cited by 116 · see citing works
Endothelial cell dysfunction: can’t live with it, how to live without it
Goligorsky, M. S. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00333.2004 · Cited by 116 · see citing works
Peroxisome proliferator-activated receptors and cardiovascular remodeling
Schiffrin, E. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00677.2004 · Cited by 110 · see citing works
Integrative Proteomics and Targeted Transcriptomics Analyses in Cardiac Endothelial Cells Unravel Mechanisms of Long-Term Radiation-Induced Vascular Dysfunction
Azimzadeh, O., Sievert, W., Sarioglu, H., Merl‐Pham, J., Yentrapalli, R., Bakshi, M. V., Janik, D., Ueffing, M., Atkinson, M. J., Multhoff, G., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr501141b · Cited by 108 · see citing works
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Simbrunner, B., Trauner, M. A., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 107 · see citing works
Coagulation and atherothrombotic disease
Ajjan, R., & Grant, P. J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.042 · Cited by 106 · see citing works
PPARα: an emerging therapeutic target in diabetic microvascular damage
Hiukka, A., Maranghi, M., Matikainen, N., & Taskinen, M.-R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.89 · Cited by 103 · see citing works
Dehydroepiandrosterone Mimics Acute Actions of Insulin to Stimulate Production of Both Nitric Oxide and Endothelin 1 via Distinct Phosphatidylinositol 3-Kinase- and Mitogen-Activated Protein Kinase-Dependent Pathways in Vascular Endothelium
Formoso, G., Chen, H., Kim, J., Montagnani, M., Consoli, A., & Quon, M. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0266 · Cited by 99 · see citing works
Resveratrol and Its Metabolites Bind to PPARs
Calleri, E., Pochetti, G., Dossou, K. S. S., Laghezza, A., Montanari, R., Capelli, D., Prada, E., Loiodice, F., Massolini, G., Bernier, M., et al. (2014) · ChemBioChem · doi:10.1002/cbic.201300754 · Cited by 100 · see citing works
Fine metabolic regulation in ruminants via nutrient–gene interactions: saturated long-chain fatty acids increase expression of genes involved in lipid metabolism and immune response partly through PPAR-α activation
Bionaz, M., Thering, B. J., & Loor, J. J. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511002777 · Cited by 100 · see citing works
SIRT1 Antagonizes Oxidative Stress in Diabetic Vascular Complication
Meng, T., Qin, W., & Liu, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.568861 · Cited by 99 · see citing works
Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators
Han, S. H., Quon, M. J., & Koh, K. K. (2005) · Hypertension · doi:10.1161/01.hyp.0000187900.36455.4c · Cited by 98 · see citing works
Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men
Ryan, K. E., McCance, D. R., Powell, L., McMahon, R., & Trimble, E. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.007 · Cited by 94 · see citing works
PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation
Okayasu, T., Tomizawa, A., Suzuki, K., Manaka, K., & Hattori, Y. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.02.002 · Cited by 91 · see citing works
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 89 · see citing works
Does reversal of oxidative stress and inflammation provide vascular protection?
Koh, K. K., Oh, P. C., & Quon, M. J. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn354 · Cited by 89 · see citing works
Fenofibrate Increases High-Density Lipoprotein and Sphingosine 1 Phosphate Concentrations Limiting Abdominal Aortic Aneurysm Progression in a Mouse Model
Krishna, S. M., Seto, S. W., Moxon, J. V., Rush, C. M., Walker, P. J., Norman, P. E., & Golledge, J. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.015 · Cited by 84 · see citing works
Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC
Murakami, H., Murakami, R., Kambe, F., Cao, X., Takahashi, R., Asai, T., Hirai, T., Numaguchi, Y., Okumura, K., Seo, H., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.052 · Cited by 81 · see citing works
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: How Their Effects on Macrophages Can Lead to the Development of a New Drug Therapy Against Atherosclerosis
Li, A. C., & Palinski, W. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141247 · Cited by 77 · see citing works
Fenofibrate Improves Vascular Endothelial Function by Reducing Oxidative Stress While Increasing Endothelial Nitric Oxide Synthase in Healthy Normolipidemic Older Adults
Walker, A. E., Kaplon, R. E., Lucking, S. M. S., Russell, M. J., Eckel, R. H., & Seals, D. R. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.203661 · Cited by 76 · see citing works
Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-α1/mTOR pathway
Pal, P. B., Sonowal, H., Shukla, K., Sk, S., & Ramana, K. V. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0080 · Cited by 75 · see citing works
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
Maccallini, C., Mollica, A., & Amoroso, R. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0220-9 · Cited by 62 · see citing works
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62 · see citing works
Clofibrate PPARα Activation Reduces Oxidative Stress and Improves Ultrastructure and Ventricular Hemodynamics in No-flow Myocardial Ischemia
Ibarra-Lara, L., Hong, E., Soria‐Castro, E., Torres-Narváez, J. C., Pérez‐Severiano, F., del Valle‐Mondragón, L., Cervantes-Pérez, L. G., Ramírez-Ortega, M. D. C., Pastelín-Hernández, G. S., & Sánchez-Mendoza, A. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31826216ed · Cited by 61 · see citing works
Protection against myocardial ischaemia/reperfusion injury by PPAR–α activation is related to production of nitric oxide and endothelin–1
Bulhak, A., Sjöquist, P.-O. B., Xu, C., Edvinsson, L. I., & Pernow, J. (2006) · Basic Research in Cardiology · doi:10.1007/s00395-005-0580-1 · Cited by 60 · see citing works
Endothelial dysfunction and reduced antioxidant protection in an animal model of the developmental origins of cardiovascular disease
Rodford, J. L., Torrens, C., Siow, R., Mann, G., Hanson, M., & Clough, G. (2008) · Journal of Physiology · doi:10.1113/jphysiol.2008.156976 · Cited by 58 · see citing works
Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Kim, J., Lee, Y., & Shin, E. K. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1418 · Cited by 57 · see citing works
PPARα as a therapeutic target in inflammation-associated diseases
Gervois, P. P., & Mansouri, R. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.715633 · Cited by 54 · see citing works
Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms
Zamblé, A., Carpentier, M., Kandoussi, A., Şahpaz, S., Pétrault, O., Ouk, T., Hennuyer, N., Fruchart, J., Staels, B., Bordet, R., et al. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000211734.53798.1d · Cited by 51 · see citing works
Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters
Singh, V., Jain, M. K., Misra, A., Khanna, V., Rana, M., Prakash, P., Malasoni, R., Dwivedi, A. K., Dikshit, M., & Barthwal, M. K. (2013) · British Journal Of Nutrition · doi:10.1017/s0007114512005363 · Cited by 51 · see citing works
Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates
Koh, K. K., Quon, M. J., Rosenson, R. S., Chung, W., & Han, S. H. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.04.080 · Cited by 48 · see citing works
Curcumin inhibits TNFα-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism
Lee, H.-S., Lee, M. J., Kim, H., Choi, S., Kim, J., Moon, H., & Park, W. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756360903555274 · Cited by 48 · see citing works
Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease
Wagner, N., & Wagner, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032345 · Cited by 48 · see citing works
Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells
Takahashi, S., & Nakashima, Y. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511003588 · Cited by 46 · see citing works
Plant polyphenols Morin and Quercetin rescue nitric oxide production in diabetic mouse aorta through distinct pathways
Taguchi, K., Tano, I., Kaneko, N., Matsumoto, T., & Kobayashi, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110463 · Cited by 46 · see citing works
Role of the Peroxisome Proliferator Activated Receptors in Hypertension
Fang, S., Livergood, M. C., Nakagawa, P., Wu, J. F., & Sigmund, C. D. (2021) · Circulation Research · doi:10.1161/circresaha.120.318062 · Cited by 44 · see citing works
Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease
He, M., Wang, D., Xu, Y., Jiang, F., Zheng, J., Feng, Y., Cao, J.-M., & Zhou, X. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071345 · Cited by 44 · see citing works
The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats
Linz, W., Wohlfart, P., Baader, M., Breitschopf, K., Falk, E., Schäfer, H., Gerl, M., Kramer, W., & Rütten, H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.58 · Cited by 44 · see citing works
Pleiotropic actions of fenofibrate on the heart
Balakumar, P., Rohilla, A., & Mahadevan, N. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.11.002 · Cited by 42 · see citing works
PPARα activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism
Ren, S., Xin, C., Beck, K., Saleem, M. A., Mathieson, P. W., Pavenstädt, H., Pfeilschifter, J. M., & Huwiler, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.158 · Cited by 42 · see citing works
Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients
Hamilton, S. J., Chew, G. T., Davis, T. M. E., & Watts, G. F. (2010) · Clinical Science · doi:10.1042/cs20090568 · Cited by 42 · see citing works
Endothelial function, arterial stiffness and lipid lowering drugs
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1143 · Cited by 41 · see citing works
Fenofibrate and metabolic syndrome
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · see citing works
“[102] reported that FF increases endothelial Nitric Oxide (NO) availability.”
Endothelial Cell Dysfunction
Davidge, S. T., de Groot, C. J. M., & Taylor, R. N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407866-6.00009-2 · Cited by 41 · see citing works
PPAR‐δ in Vascular Pathophysiology
Wang, N. (2008) · PPAR Research · doi:10.1155/2008/164163 · Cited by 40 · see citing works
PPARs in atherosclerosis: The spatial and temporal features from mechanism to druggable targets
Zheng, Y., Shao, M., Zheng, Y., Sun, W., Qin, S., Sun, Z., Zhu, L., Guan, Y., Wang, Q., Wang, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.020 · Cited by 37 · see citing works
Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein
d’Uscio, L. V., Das, P., Santhanam, A. V. R., He, T., Younkin, S. G., & Katušić, Z. S. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs266 · Cited by 34 · see citing works
Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome
Kipp, Z. A., Badmus, O. O., Stec, D. E., Hall, B., & Hinds, T. D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156081 · Cited by 33 · see citing works
Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries
de Sotomayor, M. Á., Mingorance, C., & Andriantsitohaina, R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.041 · Cited by 33 · see citing works
Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy
Heffernan, K. S., Ranadive, S. M., & Jae, S. Y. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110197 · Cited by 32 · see citing works
Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery
Romano, M. R., & Lograno, M. D. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.02.049 · Cited by 32 · see citing works
Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells
Araki, H., Tamada, Y., Imoto, S., Dunmore, B., Sanders, D. A., Humphrey, S., Nagasaki, M., Doi, A., Nakanishi, Y., Yasuda, K., et al. (2009) · Angiogenesis · doi:10.1007/s10456-009-9142-8 · Cited by 32 · see citing works
Peroxisome Proliferator-Activated Receptors and Atherosclerosis
Šoškić, S., Dobutović, B., Sudar-Milovanovic, E. M., Obradovic, M. M., Nikolić, D., Zarić, B. L., Stojanović, S. Đ., Stokić, E., Mikhailidis, D. P., & Isenović, E. R. (2011) · Angiology · doi:10.1177/0003319711401012 · Cited by 31 · see citing works
PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke
Ouk, T., Potey, C., Gautier, S., Bastide, M., Deplanque, D., Staels, B., Duriez, P., Leys, D., & Bordet, R. (2013) · Current Drug Targets · doi:10.2174/1389450111314070005 · Cited by 31 · see citing works
Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Tentolouris, A., Eleftheriadou, I., Tzeravini, E., Tsilingiris, D., Paschou, S. Α., Siasos, G., & Tentolouris, N. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190119154152 · Cited by 30 · see citing works
Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator–Activated Receptor α–Dependent and Independent Mechanisms in Human Endothelial Cells
Glineur, C., Gross, B. S., NEVE, B. P., Rommens, C., Chew, G. T., Martin‐Nizard, F., Rodríguez‐Pascual, F., Lamas, S., Watts, G. F., & Staels, B. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300665 · Cited by 30 · see citing works
CTRP13 Preserves Endothelial Function by Targeting GTP Cyclohydrolase 1 in Diabetes
Wang, C., Chao, Y., Xu, W., Liang, M., Deng, S., Zhang, D., & Huang, K. (2019) · Diabetes · doi:10.2337/db19-0635 · Cited by 30 · see citing works
Dual PPAR α/γ Agonists: Promises and Pitfalls in Type 2 Diabetes
Ahmed, I., Furlong, K., Flood, J. J., Treat, V., & Goldstein, B. J. (2007) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000212890.82339.8d · Cited by 30 · see citing works
Leukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation
Nicolete, R., Rius, C., Piqueras, L., Jose, P. J., Sorgi, C. A., Soares, E. G., Sanz, M., & Faccioli, L. H. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-36 · Cited by 28 · see citing works
The Novel Role of Fenofibrate in Preventing Nicotine- and Sodium Arsenite-Induced Vascular Endothelial Dysfunction in the Rat
Kaur, J., Reddy, K., & Balakumar, P. (2010) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9086-7 · Cited by 27 · see citing works
Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein
Yuan, J. J., Tan, J. T. M., Rajamani, K., Solly, E. L., King, E. J., Lecce, L., Simpson, P. J. L., Lam, Y. T., Jenkins, A. J., Bursill, C. A., et al. (2019) · Diabetes · doi:10.2337/db17-0926 · Cited by 27 · see citing works
PPAR‐alpha: therapeutic role in diabetes‐related cardiovascular disease
CHENG, A. Y. Y., & Leiter, L. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00747.x · Cited by 27 · see citing works
Effect of a Peroxisome Proliferator–Activated Receptor-γ Agonist on Myocardial Blood Flow in Type 2 Diabetes
McMahon, G. T., Plutzky, J., Daher, E., Bhattacharyya, T., Grunberger, G., & DiCarli, M. F. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1145 · Cited by 26 · see citing works
Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073418 · Cited by 25 · see citing works
Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy
Al‐Rasheed, N. M., Al-Rasheed, N. M., Attia, H., Alamin, M. A., Al‐Ajmi, H. N., Hasan, I. H., Mohamad, R. A., & Sinjilawi, N. A.-A. (2015) · Pharmacology · doi:10.1159/000381190 · Cited by 25 · see citing works
Peroxisome Proliferator-Activated Receptor α Activation-Mediated Regulation of Endothelin-1 Production via Nitric Oxide and Protein Kinase C Signaling Pathways in Piglet Cerebral Microvascular Endothelial Cell Culture
Yakubu, M. A., Nsaif, R. H., & Oyekan, A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104992 · Cited by 25 · see citing works
Inflammation at the blood-brain barrier: The role of liver X receptors
de Wit, N. M., Vanmol, J., Kamermans, A., Hendriks, J. J. A., & de Vries, H. E. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.09.015 · Cited by 25 · see citing works
PPARα stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner
Ibarra-Lara, L., Cervantes-Pérez, L. G., Pérez‐Severiano, F., del Valle‐Mondragón, L., Rubio-Ruiz, M. E., Soria‐Castro, E., Pastelín-Hernández, G. S., Sánchez-Aguilar, M., Martínez‐Lazcano, J. C., & Sánchez-Mendoza, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.039 · Cited by 25 · see citing works
The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia
Psilopatis, I., Vrettou, K., Fleckenstein, F. N., & Theocharis, S. E. (2023) · Cells · doi:10.3390/cells12040647 · Cited by 24 · see citing works
Effect of Berberine on PPARα/NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy
Wang, M., Wang, J., Tan, R., Wu, Q., Qiu, H., Yang, J., & Jiang, Q. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/285489 · Cited by 24 · see citing works
PPAR Activation: A New Target for the Treatment of Hypertension
Leibovitz, E., & Schiffrin, E. L. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318062153b · Cited by 24 · see citing works
An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α
Sharma, S., Sharma, D., Dhobi, M., Wang, D., & Tewari, D. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04755-7 · Cited by 23 · see citing works
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 26 · see citing works
Pretreatment with peroxysome proliferator-activated receptor α agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock
Wiel, É., Lebuffe, G., Robin, E., Gasan, G., Corseaux, D., Tavernier, B., Jude, B., Bordet, R., & Vallet, B. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2730-1 · Cited by 22 · see citing works
Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway
BLANCORIVERO, J., MARQUEZRODAS, I., XAVIER, F., ARASLOPEZ, R., ARROYOVILLA, I., FERRER, M., & BALFAGON, G. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.006 · Cited by 21 · see citing works

Fenofibrate increases endothelial nitric oxide synthase expression in bovine aortic endothelial cells
Li, Z. (2004) · Zhongguo bingli shengli zazhi
Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells
Wang, Y., Wang, Y., Yang, Q., Yan, J., Zhao, C., Cianflone, K., & Wang, D. W. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.09.008 · Cited by 40 · see citing works
Bezafibrate up-regulate endothelial nitric oxide gene expressions via peroxisome proliferator-activated receptors alpha-dependent and independent pathways in cultured Bovine endothelial cells
Dao-we, W. (2006) · Zhonghua xinxueguanbing zazhi
The peroxisome proliferator‐activated receptor alpha agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung
Becker, J., Delayre‐Orthez, C., Frossard, N., & Pons, F. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00935.x · Cited by 11 · see citing works
PPARs ligands antagonizes Ang-induced decrease in endothelial NO production by upregulating eNOS expression
Shi-ming, L. (2006) · Zhongguo bingli shengli zazhi

Authors: Goya, K., Sumitani, S., Xu, X., Kitamura, T., Yamamoto, H., Kurebayashi, S., Saito, H., Kouhara, H., Kasayama, S., & Kawase, I.
Affiliations: The University of Osaka (JP)
ORCID: Xu, Xin
Kitamura, Tetsuhiro
Yamamoto, Hiroyasu
Saito, Hiroshi
Kasayama, Soji
Kawase, Ichiro
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-04
Volume: 24
Issue: 4
Pages: 658-663
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/01.atv.0000118682.58708.78
OpenAlex: W2110733021
Cited by: 174
References: 47
Citations by year: 2026: 1 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 9 · 2017: 1 · 2016: 7 · 2015: 4 · 2014: 7 · 2013: 13 · 2012: 16
FWCI: 5.56
Type: journal article
Language: en
Open access: closed
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: PPARα agonist, endothelial nitric oxide synthase, fenofibrate, bezafibrate, Wy-14,643, rosiglitazone, RU486, vascular endothelial cells, cardioprotection
MeSH terms: Rosiglitazone, Animals, Aorta, Bezafibrate, Cattle, Cells, Cultured, Dactinomycin, Endothelium, Vascular, Enzyme Induction, Half-Life, Nitric Oxide, Fenofibrate, Pyrimidines, RNA, Messenger, Transcription Factors, Transcription, Genetic, Transfection, Mifepristone, Gene Expression Regulation, Enzymologic, Receptors, Cytoplasmic and Nuclear, Nitric Oxide Synthase, Endothelial Cells, Thiazolidinediones, Nitric Oxide Synthase Type III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks